Skip to main content

Fiscal Wizard · Single-issue tearsheet

BMRN / Oct 1, 2026 Run #19121
Paper trade

BMRN

BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; and KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Composite verdict

B 71.9 / 100
Bullish setup · Mean Reversion 12 drivers · 3 gates blocking
  • Engulfing
  • Wedge Pattern
  • Stochastic Cross
Consider long call target Δ ~0.60 · ~35 DTE Bullish setup, Grade B → ITM call target

Industry rank 5th of 21 in Biotechnology

Russell 1000 onboarding 2026-10-01
Technical synthesisRegime: uptrend
Bull 100%Evidence: High · 21 signals0% Bear
Momentum Neutral 53Mean-reversion Bullish 88
  • Pullback buyOversold in an uptrend — a pullback buy: mean-reversion aligned with the primary trend, the high-value case for an oversold signal. (medium confidence)
Where value comes fromMargin of safety -35%
Asset value $31.45Earnings power value $20.64Price $58.97

Priced above its no-growth earnings power value ($20.64/share) — you're paying for growth and franchise expansion, not just current earnings.

Fundamentals Mixed

44.5 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
EV/FCF 81
OCF to Net Income 0
EV/Sales 79
Cash Conversion 0
P/B 77
EPS Growth (YoY) 0

Technicals Bullish

99.3 / 100

Bullish setup leads (Engulfing, Wedge Pattern, Stochastic Cross); bears gated by guards. · 44 signals shown.

Strongest
Weakest
Engulfing 86
Wedge Pattern 84
Stochastic Cross 83

Risk Gates

3 blocking 6 caution

3 guards active, 22 signals gated.

ADX Trend Weakness Blocking

Weak trend strength blocks trend-following signals in either direction.

Realized Volatility Regime Blocking

High-vol regime mutes mean-reversion signals; low-vol regime mutes breakout signals.

Regime Filter Blocking

Blocks signals that oppose the long-term moving-average regime.

Cash Ratio Caution

Visual cash-cushion flag — does not mute signals.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for BMRN.